What Has Been The Evolution of the Histone Deacetylase Inhibitors Market in Recent Years?
The histone deacetylase inhibitors market has seen considerable growth due to a variety of factors.
• The histone deacetylase inhibitors market has seen strong growth in recent years. It will grow from $1.2 billion in 2024 to $1.3 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.2%.
The growth in the historical period can be attributed to regulatory support and fast-track approvals, a growing cancer prevalence, more funding for cancer research, an expanding range of therapeutic applications, and increased healthcare infrastructure investments.
What Is the Forecasted Market Size and Growth Rate for The Histone Deacetylase Inhibitors Market Size In The Coming Years?
The histone deacetylase inhibitors market is expected to maintain its strong growth trajectory in upcoming years.
• The histone deacetylase inhibitors market is set to grow to $1.77 billion by 2029 at a CAGR of 7.9%.
Growth drivers include increased biotechnology investment, the aging population, favorable regulatory approvals, faster drug approvals, improved delivery systems, and expanded therapeutic applications. Trends include wearable device integration, nanotechnology advancements, drug delivery innovations, AI and machine learning, and next-gen sequencing.
What Factors Are Driving Growth In The Histone Deacetylase Inhibitors Market?
The growth of the marine industry is expected to drive the hoist market. The marine industry involves transportation activities related to waterways, including oceans and rivers. The rise of the marine industry is attributed to factors such as globalization, increased trade, e-commerce, and advancements in maritime technology. Hoists are critical tools in the marine industry, improving safety, efficiency, and precision in shipyards, ports, and offshore platforms. According to the Bureau of Economic Analysis, the U.S. marine economy contributed $476.2 billion to the GDP in 2022, up from $424.2 billion in 2021. Therefore, the growth of the marine industry is driving the hoist market.
What Are The Main Segments Of The Global Histone Deacetylase Inhibitors Market?
The histone deacetylase inhibitors market covered in this report is segmented –
1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Suubsegments:
1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)
Pre-Book The Histone Deacetylase Inhibitors Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Histone Deacetylase Inhibitors Market?
Leading enterprises within the histone deacetylase inhibitors industry are emphasizing the development of innovative product formulations such as oral histone deacetylase (HDAC) inhibitors, intending to broaden the available treatment modalities and enhance the convenience and compliance of patients. Oral histone deacetylase (HDAC) inhibitor is a medication consumed orally that targets HDAC enzymes pivotal for gene regulation, and has potential applications in treating a range of health conditions, including cancer and inflammation-based ailments. For instance, in March 2024, Italfarmaco S.p.A., a pharmaceutical firm based in Italy, secured approval from the Food and Drug Administration for Duvyzat (givinostat), an oral HDAC inhibitor, intended for treating Duchenne muscular dystrophy (DMD) in patients aged six years and above. Duvyzat, a HDAC inhibitor, curtails the events leading to muscle damage, thereby potentially decelerating the progression of muscle degeneration associated with DMD. By restraining HDAC hyperactivity, it diminishes inflammation and fibrosis, while fostering the regeneration of muscle fibers. The approval was granted based on the results from the critical phase 3 EPIDYS trial, indicating a statistically significant reduction in the time taken by patients on Duvyzat to complete the four-stair climb evaluation in comparison to a placebo.
Who Are the Key Players In The Histone Deacetylase Inhibitors Market?
Major companies operating in the histone deacetylase inhibitors market are:
• Merck & Co. Inc.
• AstraZeneca plc
• Novartis AG
• Eisai Co. Ltd.
• Aurobindo Pharma Limited
• Karyopharm Therapeutics Inc.
• Syndax Pharmaceuticals Inc.
• MEI Pharma Inc.
• Italfarmaco S.p.A.
• Tokyo Chemical Industry Co. Ltd.
• InvivoGen Corp.
• Huya Bioscience International LLC
• Crystal Genomics Inc.
• Spectrum Pharmaceuticals Inc.
• Curis Inc.
• Celgene Corporation
• Celleron Therapeutics
• Medivir AB
• Onxeo SA
• Regenacy Pharmaceuticals Inc.
• Shenzhen Chipscreen Biosciences Co. Ltd.
• Wellness Pharma International LLC
• Forum Pharmaceuticals Inc.
• Midatech Pharma PLC
What Is The Most Dominant Region In The Histone Deacetylase Inhibitors Market?
North America was the largest region in the histone deacetylase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
